NASDAQ:TENX Tenax Therapeutics Q2 2026 Earnings Results & Report $1.87 +0.01 (+0.54%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$1.87 0.00 (0.00%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Tenax Therapeutics beat analyst earnings expectations in its Q2 2026 results, released July 31, 2026. The company reported EPS of -$0.35 versus the -$0.3813 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateJuly 31, 2026TimeBefore Market OpensConference Call7:30 AM ET Tenax Therapeutics EPS ResultsActual EPS-$0.35Consensus EPS -$0.3813Beat/MissBeat by +$0.0313One Year Ago EPSN/AEPS Beat Rate8 of last 8 quartersTenax Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsTenax Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Tenax Therapeutics Q2 2026 Earnings FAQ Did Tenax Therapeutics beat earnings estimates for Q2 2026? Tenax Therapeutics (NASDAQ:TENX) reported earnings of -$0.35 per share for Q2 2026, beating the consensus estimate of -$0.3813. The report was announced on Friday, July 31, 2026. When is Tenax Therapeutics' next earnings date? Tenax Therapeutics' next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Tenax Therapeutics on the company's earnings history page. Tenax Therapeutics Earnings HeadlinesPiper Sandler Remains a Buy on Tenax Therapeutics (TENX)September 16, 2026 | theglobeandmail.comTenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable?September 4, 2026 | insidermonkey.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. | Banyan Hill Publishing (Ad)Guggenheim downgrades Tenax Therapeutics (TENX)September 2, 2026 | msn.comTenax Therapeutics to Participate in the 2026 Cantor Global Healthcare ConferenceSeptember 1, 2026 | globenewswire.comTenax's Phase 3 Study For TNX-103 Fails To Meet Primary Endpoint; Shows Success In Other MeasuresAugust 30, 2026 | rttnews.comSee More Tenax Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tenax Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tenax Therapeutics and other key companies, straight to your email. Email Address About Tenax TherapeuticsTenax Therapeutics (NASDAQ:TENX) is a specialty pharmaceutical company focused on developing treatments for cardiovascular and pulmonary diseases with significant unmet medical needs. The company’s research and development activities are centered on therapies intended to improve outcomes for patients with conditions affecting the heart and lungs. Tenax’s primary product candidate is an oral formulation of levosimendan, a drug designed to enhance cardiac contractility and produce vasodilatory effects. The company has been evaluating the therapy, also referred to as TNX-103, for pulmonary hypertension associated with heart failure with preserved ejection fraction, a condition for which treatment options remain limited. The company conducts its development activities primarily in the United States and has focused on advancing levosimendan through clinical development and regulatory review. Tenax Therapeutics was formerly known as Oxygen Biotherapeutics and adopted its current name in 2015. The company is headquartered in Morrisville, North Carolina, and its common stock trades on the Nasdaq under the symbol TENX.View Tenax Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
